Media stories about Paratek Pharmaceuticals (NASDAQ:PRTK) have been trending somewhat positive on Tuesday, according to Accern Sentiment. The research group ranks the sentiment of press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Paratek Pharmaceuticals earned a coverage optimism score of 0.22 on Accern’s scale. Accern also assigned news stories about the specialty pharmaceutical company an impact score of 46.3072730098663 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Paratek Pharmaceuticals (NASDAQ PRTK) opened at 26.45 on Tuesday. The firm’s market cap is $734.28 million. The stock’s 50 day moving average is $22.38 and its 200-day moving average is $21.26. Paratek Pharmaceuticals has a 12 month low of $9.80 and a 12 month high of $29.00.
Paratek Pharmaceuticals (NASDAQ:PRTK) last announced its earnings results on Wednesday, August 2nd. The specialty pharmaceutical company reported ($0.64) EPS for the quarter, topping the consensus estimate of ($0.89) by $0.25. The company had revenue of $7.51 million for the quarter, compared to the consensus estimate of $7.50 million.
A number of research firms have issued reports on PRTK. BidaskClub upgraded shares of Paratek Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, August 10th. Cantor Fitzgerald restated an “overweight” rating and set a $50.00 price target on shares of Paratek Pharmaceuticals in a report on Thursday, June 22nd. Zacks Investment Research cut shares of Paratek Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, August 8th. Finally, Raymond James Financial, Inc. restated a “strong-buy” rating and set a $36.00 price target on shares of Paratek Pharmaceuticals in a report on Thursday, August 24th. Two equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. Paratek Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $37.44.
TRADEMARK VIOLATION NOTICE: This news story was reported by Markets Daily and is the property of of Markets Daily. If you are reading this news story on another publication, it was illegally stolen and republished in violation of United States & international copyright & trademark law. The correct version of this news story can be viewed at https://www.themarketsdaily.com/2017/09/12/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-paratek-pharmaceuticals-prtk-stock-price.html.
In related news, VP Adam Woodrow sold 3,800 shares of Paratek Pharmaceuticals stock in a transaction dated Wednesday, July 5th. The shares were sold at an average price of $23.58, for a total transaction of $89,604.00. Following the completion of the sale, the vice president now owns 69,500 shares of the company’s stock, valued at approximately $1,638,810. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Douglas W. Pagan sold 4,595 shares of the business’s stock in a transaction dated Monday, June 19th. The shares were sold at an average price of $25.00, for a total transaction of $114,875.00. Following the completion of the sale, the chief financial officer now directly owns 51,000 shares of the company’s stock, valued at approximately $1,275,000. The disclosure for this sale can be found here. Insiders have sold a total of 21,960 shares of company stock valued at $524,342 in the last ninety days. 4.90% of the stock is currently owned by insiders.
Paratek Pharmaceuticals Company Profile
Paratek Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections.
Receive News & Ratings for Paratek Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.